1. S. Abhulimen and A. Hirsch, ‘Quantifying the economic impact of a digital self-care behavioral health platform on Missouri Medicaid expenditures’, Journal of Medical Economics, vol. 21, no. 11, pp. 1084–1090, Nov. 2018, doi: https://doi.org/10.1080/13696998.2018.1510834.
2. AMCP Forum, ‘AMCP Partnership Forum: Digital Therapeutics—What Are They and Where Do They Fit in Pharmacy and Medical Benefits?’, JMCP, vol. 26, no. 5, pp. 674–681, May 2020, doi: https://doi.org/10.18553/jmcp.2020.19418.
3. S. Bias, ‘Assessing Barriers to Inclusion of Digital Therapeutics on Formulary: A Cross-Sectional Study Across Health Plans, PBMs, and IDNs’, presented at the AMCP Nexus 2019, Oct. 2019.
4. CBPartners, ‘Access to Digital Therapeutics in a Post-COVID-19 World’, CBPartners, Jul. 14, 2020. https://www.cbpartners.com/access-to-digital-therapeutics-in-a-post-covid-19-world/ (accessed Dec. 28, 2020).
5. Center for Devices and Radiological Health, ‘What is Digital Health?’, FDA, Sep. 2020, Accessed: Dec. 27, 2020. [Online]. Available: https://www.fda.gov/medical-devices/digital-health-center-excellence/what-digital-health.